108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
一项评估 QP002 治疗开放性单侧腹股沟疝无张力修补术后疼痛的安全性、耐受性、药代动力学和疗效的 I 期研究
Authors Yang L, Liu J , Liu S, Cao D, Xie K, Zhang X , Yang M
Received 27 January 2025
Accepted for publication 1 September 2025
Published 2 October 2025 Volume 2025:19 Pages 8985—8995
DOI https://doi.org/10.2147/DDDT.S518200
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Manfred Ogris
Lina Yang,1,* Jinyu Liu,2,* Shaoxing Liu,3 Dejun Cao,3 Keyu Xie,3 Xianjie Zhang,4 Mengchang Yang5
1Department of Anesthesiology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 2Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, People’s Republic of China; 3Department of Anesthesiology, Chengdu Second People’s Hospital, Chengdu, People’s Republic of China; 4Department of Anesthesiology, Deyang People’s Hospital, Deyang, People’s Republic of China; 5Clinical Trial Centre, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Mengchang Yang, Email ymc681@126.com
Background: QP002 Long-acting local anaesthetic with bupivacaine and low-dose meloxicam as active ingredients for postoperative regional analgesia. The objective of the present study was to evaluate the safety, tolerability, and pharmacokinetics (PK) and pharmacodynamics (PD) of QP002 for postoperative analgesia following tension-free repair of an open unilateral inguinal hernia.
Methods: This was a multicentre, randomised, double-blind, positive-controlled trial. Patients were randomly assigned to receive a single injection of QP002 (five dose groups) with 0.25% bupivacaine hydrochloride 75 mg after open unilateral tension-free repair of an inguinal hernia. Pharmacokinetic parameters were evaluated by obtaining pharmacokinetic characteristic blood samples before and 120 hours after administration, at a total of 20 sampling points. Adverse events occurring after treatment were recorded from baseline to postoperative day 27 follow-up.
Results: A total of 40 patients with unilateral inguinal hernia were included in this study. In comparison to 0.25% bupivacaine hydrochloride 75 mg, the results demonstrate that QP002 was well tolerated, with no additional adverse events (AEs) observed and no instances of serious adverse events (SAEs). QP002 demonstrated prolonged absorption and clearance of bupivacaine, including a longer time to reach peak plasma concentration and a terminal elimination half-life. The peak plasma concentrations of 240 mg/7.2 mg QP002 (Cmax 250.33 ng/mL) were similar to those of 0.25% bupivacaine hydrochloride 75 mg (Cmax 258.40 ng/mL). Cumulative pain intensity scores at 24 hours postoperatively in the exercise state (NRS-A-AUC0-24) were lower in the QP002 dose groups than in the 0.25% bupivacaine hydrochloride 75 mg, with P = 0.0165 in the 320 mg/9.6 mg QP002 and P = 0.0435 in the 400 mg/12 mg QP002.
Conclusion: QP002 demonstrated favorable safety profiles and exhibited distinct extended-release pharmacokinetic (PK) characteristics in single-ascending-dose administration. High doses of QP002 showed potential for postoperative incisional infiltration to control pain. Future studies will further explore its efficacy and safety in broader clinical applications.
Keywords: QP002, phase I trial, pharmacokinetic, safety
1Department of Anesthesiology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 2Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, People’s Republic of China; 3Department of Anesthesiology, Chengdu Second People’s Hospital, Chengdu, People’s Republic of China; 4Department of Anesthesiology, Deyang People’s Hospital, Deyang, People’s Republic of China; 5Clinical Trial Centre, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Mengchang Yang, Email ymc681@126.com
Background: QP002 Long-acting local anaesthetic with bupivacaine and low-dose meloxicam as active ingredients for postoperative regional analgesia. The objective of the present study was to evaluate the safety, tolerability, and pharmacokinetics (PK) and pharmacodynamics (PD) of QP002 for postoperative analgesia following tension-free repair of an open unilateral inguinal hernia.
Methods: This was a multicentre, randomised, double-blind, positive-controlled trial. Patients were randomly assigned to receive a single injection of QP002 (five dose groups) with 0.25% bupivacaine hydrochloride 75 mg after open unilateral tension-free repair of an inguinal hernia. Pharmacokinetic parameters were evaluated by obtaining pharmacokinetic characteristic blood samples before and 120 hours after administration, at a total of 20 sampling points. Adverse events occurring after treatment were recorded from baseline to postoperative day 27 follow-up.
Results: A total of 40 patients with unilateral inguinal hernia were included in this study. In comparison to 0.25% bupivacaine hydrochloride 75 mg, the results demonstrate that QP002 was well tolerated, with no additional adverse events (AEs) observed and no instances of serious adverse events (SAEs). QP002 demonstrated prolonged absorption and clearance of bupivacaine, including a longer time to reach peak plasma concentration and a terminal elimination half-life. The peak plasma concentrations of 240 mg/7.2 mg QP002 (Cmax 250.33 ng/mL) were similar to those of 0.25% bupivacaine hydrochloride 75 mg (Cmax 258.40 ng/mL). Cumulative pain intensity scores at 24 hours postoperatively in the exercise state (NRS-A-AUC0-24) were lower in the QP002 dose groups than in the 0.25% bupivacaine hydrochloride 75 mg, with P = 0.0165 in the 320 mg/9.6 mg QP002 and P = 0.0435 in the 400 mg/12 mg QP002.
Conclusion: QP002 demonstrated favorable safety profiles and exhibited distinct extended-release pharmacokinetic (PK) characteristics in single-ascending-dose administration. High doses of QP002 showed potential for postoperative incisional infiltration to control pain. Future studies will further explore its efficacy and safety in broader clinical applications.
Keywords: QP002, phase I trial, pharmacokinetic, safety